News >

Targeted Therapies, Triplet Regimens Becoming Focus in Biliary Tract Cancers

Gina Columbus @ginacolumbusonc
Published: Monday, Feb 04, 2019

Rachna T. Shroff, MD, MS

Rachna T. Shroff, MD, MS

In an effort to move away from standard combination chemotherapy, researchers are looking at additional regimens for patients with biliary tract cancers, as well as turning their focus to molecular profiling, explained Rachna T. Shroff, MD, MS.

“The biggest challenge is that, to date, we have one standard of care treatment, and that is gemcitabine and platinum[-based therapy]. And, that has been the standard of care for years,” said Shroff, an associate professor of medicine, chief, Section of GI Medical Oncology, leader of the GI Disease-Oriented Team, chair of the Data Safety Monitoring Board, University of Arizona Cancer Center.

The ongoing phase III SWOG 1815 trial (NCT03768414) trial is evaluating the regimen of gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel (Abraxane) in 268 patients with newly diagnosed, advanced biliary tract cancers. The primary endpoint is overall survival (OS); secondary endpoints include progression-free survival (PFS), overall response rate, disease control rate (DCR), safety, and the correlation between CA19-9 levels from baseline to posttreatment.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication